Table 2 Adjusted odds ratio (OR) and 95% confidence intervals (CI) of diagnostic wait times by demographic and tumour characteristics for screen, interval and symptomatic detected breast cancers
Screen-detected (N = 1181) | Interval (N = 319) | Symptomatic (N = 406) | |||||||
|---|---|---|---|---|---|---|---|---|---|
Characteristics | n (%) | ORa | n (%) | ORa | n (%) | ORa | |||
Wait time | <=31 days | >31 days | (95% CI) | <=20 days | >20 days | (95% CI) | <=7 days | >7 days | (95% CI) |
Overall | 599(50.7) | 582 (49.3) | 159 (49.8) | 160 (51.2) | 207 (49.0) | 199 (51.0) | |||
Age at diagnosis a | |||||||||
50-59 | 232 (38.7) | 218 (37.5) | 1.00 (reference) | 70 (43.8) | 52 (32.7) | 1.00 (reference) | 79 (38.2) | 86 (43.2) | 1.00 (reference) |
60-69 | 367 (61.3) | 364 (62.5) | 0.91(0.61-1.37) | 90 (56.5) | 107 (67.3) | 0.55(0.24-1.21) | 128 (61.8) | 113 (56.8) | 1.05(0.50-2.18) |
Period of diagnosis a | |||||||||
1995-1999 | 335 (55.9) | 317 (54.5) | 1.00 (reference) | 79(49.4) | 69 (43.4) | 1.00 (reference) | 121 (58.5) | 125 (62.8) | 1.00 (reference) |
2000-2003 | 264 (44.1) | 265 (45.5) | 0.73(0.46-1.14) | 81(50.6) | 90 (56.6) | 1.72(0.73-4.07) | 86 (41.6) | 74 (37.2) | 0.58(0.26-1.29) |
Last screen a | |||||||||
OBSP | 206 (34.4) | 221 (38.0) | 1.00 (reference) | 74 (46.3) | 49 (30.8) | 1.00 (reference) | -- | -- | -- |
OHIP | 393 (65.6) | 361 (62.0) | 0.87(0.69-1.13) | 86 (53.8) | 110 (69.2) | 1.93(1.20-3.10)* | -- | -- | -- |
Treatment center region a | |||||||||
South Central | 269 (44.9) | 261 (44.9) | 1.00 (reference) | 71 (44.4) | 79 (49.7) | 1.00 (reference) | 98 (29.5) | 95 (47.7) | 1.00 (reference) |
South Eastern | 160 (26.7) | 137 (23.5) | 0.86(0.65-1.16) | 45 (28.1) | 25 (15.7) | 0.47(0.25-0.85)* | 61 (29.5) | 34 (17.1) | 0.58(0.35-0.97)* |
South Western | 111 (18.5) | 108 (18.6) | 0.99(0.72-1.36) | 28 (17.5) | 28 (17.6) | 0.87(0.46-1.63) | 34 (16.4) | 37 (18.6) | 1.17(0.68-2.02) |
Northern | 59 (9.90) | 76 (13.1) | 1.29(0.88-1.89) | 16 (10.0) | 27 (16.9) | 1.50(0.73-3.06) | 14 (6.8) | 33 (16.6) | 2.52(1.26-5.03)* |
Income quintiles a | |||||||||
1 | 102 (17.1) | 83 (14.3) | 1.00 (reference) | 22 (14.0) | 21 (13.4) | 1.00 (reference) | 51 (25.0) | 43 (22.1) | 1.00 (reference) |
2 | 102 (17.1) | 119 (20.5) | 1.43 (0.96-2.11) | 25 (15.9) | 31 (19.8) | 1.25(0.55-2.82) | 35 (17.2) | 36 (18.5) | 1.24 (0.68-2.31) |
3 | 117 (19.6) | 107 (18.5) | 1.13 (0.76-1.66) | 39 (24.8) | 33 (21.0) | 0.84 (0.39-1.83) | 30 (14.7) | 34 (17.4) | 1.34 (0.71-2.54) |
4 | 115 (19.3) | 131 (22.6) | 1.40 (0.95-2.05) | 27 (17.2) | 24 (15.3) | 0.86 (0.37-1.98) | 44 (21.6) | 34 (17.4) | 0.89 (0.48-1.63) |
5 | 161 (27.0) | 140 (24.1) | 1.08 (0.75-1.56) | 44 (27.5) | 48 (30.6) | 1.13 (0.54-2.37) | 44 (21.6) | 48 (24.6) | 1.28 (0.72-2.27) |
Community size a | |||||||||
1 500 000+ | 150 (25.1) | 208 (35.7) | 1.00 (reference) | 48 (30.0) | 61 (38.4) | 1.00 (reference) | 68(32.8) | 71 (36.0) | 1.00 (reference) |
500 000–1 499 999 | 128 (21.4) | 77 (13.2) | 0.42(0.29-0.61)* | 28 (17.5) | 17 (10.7) | 0.41(0.20-0.85)* | 35 (16.9) | 19 (9.55) | 0.53(0.27-1.01) |
100 000–499 999 | 151 (25.2) | 146 (25.1) | 0.68(0.50-0.93)* | 39 (24.4) | 37 (23.3) | 0.68(0.37-1.24) | 34 (16.4) | 44(22.1) | 1.22(0.70-2.15) |
10 000 – 99 999 | 62 (10.4) | 58 (9.97) | 0.65(0.42-0.99)* | 21 (13.1) | 21 (13.2) | 0.77(0.37-1.59) | 29 (14.0) | 32 (16.1) | 1.08(0.59-1.97) |
<10 000 | 108 (18.0) | 93 (16.0) | 0.60(0.42-0.86)* | 24 (15.0) | 23 (14.5) | 0.71(0.35-1.44) | 41 (19.8) | 33 (16.6) | 0.78(0.45-1.40) |
Biopsy type b | |||||||||
FNA/Core | 381(63.6) | 237(40.7) | 1.00 (reference) | 110(68.8) | 70(44.0) | 1.00 (reference) | 167(80.7) | 92(46.2) | 1.00 (reference) |
Open | 218(36.4) | 345(59.3) | 2.76(2.14-3.56)* | 50 (31.3) | 89 (56.0) | 2.56(1.50-4.35)* | 41 (19.3) | 107 (53.8) | 5.56(3.33-9.30)** |
Tumour size c | |||||||||
<1.0 | 160 (27.4) | 224 (39.2) | 1.00 (reference) | 30 (20.3) | 54 (34.4) | 1.00 (reference) | 14 (7.54) | 25 (13.7) | 1.00 (reference) |
1.0-1.5 | 125 (21.4) | 143 (25.0) | 0.80(0.58-1.11) | 28 (18.92) | 33 (21.0) | 0.73(0.35-1.13) | 17 (9.14) | 29 (15.9) | 0.96(0.36-2.54) |
1.5-2.0 | 121 (20.7) | 88 (15.4) | 0.56(0.39-0.80)* | 30 (20.3) | 20 (12.7) | 0.38(0.17-0.83) | 27 (14.5) | 35 (19.1) | 0.84(0.33-2.12) |
>2.0 | 179 (30.6) | 117 (20.5) | 0.50(0.36-0.69)** | 60 (40.5) | 50 (31.9) | 0.56(0.30-1.08) | 128 (68.8) | 94 (51.4) | 0.49(0.22-1.05) |
Stage at diagnosis c | |||||||||
I | 309 (53.5) | 353 (64.2) | 1.00 (reference) | 65 (43.3) | 85 (55.6) | 1.00 (reference) | 37 (19.1) | 55 (28.4) | 1.00 (reference) |
II | 194 (33.6) | 138 (25.1) | 0.66(0.50-0.87)* | 51 (34.0) | 39 (25.5) | 0.80(0.45-1.43) | 81 (41.8) | 78 (41.9) | 0.66(0.37-1.18) |
III-IV | 75 (13.0) | 59 (10.7) | 0.72(0.49-1.06) | 34 (227) | 29(19.0) | 0.72(0.37-1.36) | 76 (39.2) | 53 (28.5) | 0.46(0.25-0.85)* |
Nodal status c | |||||||||
Negative | 386 (67.6) | 393 (72.6) | 1.00 (reference) | 93 (64.6) | 98(67.1) | 1.00 (reference) | 83 (49.7) | 99 (55.3) | 1.00 (reference) |
Positive | 185 (32.4) | 148 (27.4) | 0.83 (0.63-1.08) | 51 (35.4) | 47 (32.4) | 1.02(0.60-1.73) | 84 (50.8) | 80 (44.7) | 0.79(0.48-1.27) |